Similar Items: Disproportionality analysis of fondaparinux associated adverse events based on the FDA adverse event reporting system
- Exploring adverse events associated with vosoritide monotherapy: Insights from the FDA Adverse Event Reporting System
- Adverse events in different administration routes of Edaravone: A pharmacovigilance study based on the FDA adverse event reporting system
- Cancer risk associated with DPP4 inhibitors in type 2 diabetes: A pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS)
- Effect of intravenous vitamin C administration on chemotherapy-induced adverse events in patients with nasopharyngeal cancer
- Soluble ST2 as a biomarker for predicting severe adverse events among pediatric patients with Mycoplasma pneumoniae pneumonia
- Incidence and risk factors of perioperative respiratory adverse events in pediatric surgical patients: Development and validation of a predictive model in Brazil